Healthcare Industry Thought Leadership

Health Union’s data-driven industry conversations help pharma make smarter, more effective decisions. Check out our latest thought leadership pieces below.

How Condition-Specific Stories Fuel Engagement in Social Health

August 15, 2022

Impactful patient leader stories supported by active moderation creates ongoing, condition-specific engagement, and ultimately, trust in social health.

Rise of Influencer Marketing: Patient Leaders Bring Value to Campaigns

July 26, 2022

Influencer marketing campaigns with patient leaders represent a significant opportunity to reach socially engaged, difficult-to-reach health audiences.

Building Insights for Patient Focused Drug Development: Understanding Patient Desires and Barriers

July 12, 2022

The COVID-19 pandemic continues to revolutionize the role of the patient voice in drug development and clinical trial creation and execution.

No Vacation from Condition Management: What Summer Means for Patients & Pharma

July 11, 2022

Patient perspectives on managing chronic condition(s) during the summer can help pharma marketers craft accurate, authentic, and season-specific messaging.

Let’s Talk About Sex: Why Treating Intimacy As a Clinical Symptom Matters

February 5, 2021

Findings from Health Union’s In America surveys show sex and intimacy can be greatly impacted by a person’s condition, including symptoms and side effects.

The Year of Substance: Finding Success During 2020 and Beyond

January 22, 2021

For Health Union in 2020, substance can be attributed to our mission and core values, a strong people-first culture and the ability to adapt.

5 Ways to Make Your Pharma Marketing More Personal

January 20, 2021

Break through the noise and reach and engage people during their unique health journey with our tips to help personalize your pharma marketing strategies.

The Positive Impact of CFTR Modulators: a Year-Over-Year Comparison

December 22, 2020

Current CFTR modulator usage increased from nearly half of respondents in 2019, when three modulators were approved, to 68% in 2020.

Healthcare Industry Thought Leadership

Contact